文献速递脊柱关节炎

JAK1选择性抑制剂治疗脊柱关节炎

JAK1 selective inhibitors for the treatment of spondyloarthropathies.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本文综述了JAK1选择性抑制剂治疗脊柱关节炎(SpA),尤其是强直性脊柱炎(AS)和银屑病关节炎(PsA)的2期和3期临床试验数据。选择性JAK1抑制提供有前景的治疗途径,但需更长期试验以充分确定其在高剂量下的疗效和安全性及在更广泛SpA连续体中的应用。

要点

  • JAK介导的信号转导是SpA的潜在治疗靶点。
  • 选择性JAK1抑制在AS和PsA的2/3期试验中显示前景。
  • 需更长期试验确认高剂量疗效安全性及广泛SpA应用。

核心结论

  • 选择性JAK1抑制是治疗SpA的有前景方法,但需更长期试验充分确立其在高剂量下的疗效和安全性及在更广泛SpA连续体中的使用。

研究设计与样本

  • 综述总结了评估JAK1选择性抑制剂治疗SpA(尤其是AS和PsA)的当前2期和3期临床试验数据。

主要发现

  • 选择性较低的JAK抑制剂疗效和安全性特征不一,促使研究选择性JAK1抑制。

局限性

  • 需更长期试验以充分确定JAK1选择性抑制剂在高剂量下的疗效和安全性及其在更广泛SpA连续体中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As our understanding of the pathogenesis of SpA improves, focus has turned to the role janus kinase (JAK)-mediated signal transduction and inhibiting its actions as a therapeutic mechanism. Small molecule inhibitors of JAK exist, with variable selectivity for the different JAK isoforms. Less selective JAK inhibitors have variable efficacy and safety profiles, prompting the investigation of selective JAK1 inhibition. In this review, we summarize the current phase 2 and 3 clinical trial data, evaluating the use of JAK1 selective inhibitors in the treatment of SpA, particularly AS and PsA. Selective JAK1 inhibition offers a promising therapeutic approach, however further longer-term trials are needed to fully establish their efficacy and safety at higher doses, and their use in the greater continuum of SpA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. White JPE, Coates LC. JAK1 selective inhibitors for the treatment of spondyloarthropathies. Rheumatology (Oxford). 2021. PMID: 33950224. doi:10.1093/rheumatology/keaa815

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。